Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Laboratory evaluation of the new Clareon hydrophobic acrylic IOL material: biomaterial properties and capsular bag behavior

Poster Details

First Author: G.Auffarth GERMANY

Co Author(s):    S. Schickhardt   Q. Wang   H. Fang   F. Hengerer           

Abstract Details

Purpose:

The objective was to determine in an vitro study optical and biomechanical properties of the new Alcon Clareon SY60WF Intraocular Lens (IOL) material.

Setting:

David J. Apple International Laboratory for Ocular Pathology, Department of Ophthalmology, University of Heidelberg, Germany

Methods:

In vitro evaluation included experimental glistenings induction, surface interaction with cohesive ophthalmic viscolelastic devices (OVD), capsular bag behavior during implantation via various injector systems and capsular bag stretching and fitting of the lens. The IOL was tested using the Miyake-Apple posterior video technique in human autopsy eyes.

Results:

Glistenings formation was quantified using a dedicated image analysis software. The Clareon material was glistenings free with similar values as the B&L Envista IOL used as a comparison. OVD interaction was equivalent to the known Acrysof material with easy removal and equivalent removal times under standardized settings. When comparing capsular bag fitting and stretching of the bag equator the Clareon IOL seems to be superior to the Acrysof material due to slightly softer biomechanical material properties.

Conclusions:

With the new Clareon material Implantation behavior and OVD interaction was equivalent to the current Acrysof IOL. Clareon material proved to be glistenings free and seemed to be slightly softer thus causing less posterior capsule striae and distortions.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives non-monetary benefits from a competing company., receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented., receives consulting fees, retainer, or contract payments from a competing company

Back to Poster listing